基于CT影像组学构建胃癌新辅助免疫治疗联合化疗疗效的预测模型

Construction of a predictive model for efficacy of neoadjuvant immunotherapycombined with chemotherapy in gastric cancer based on CT radiomics

  • 摘要:
    目的 探讨基于CT影像组学构建的预测模型对于局部进展期胃癌(locally advanced gastric cancer,LAGC)新辅助免疫治疗联合化疗疗效的预测价值。
    方法 回顾性收集2019年6月至2021年6月邢台医学高等专科学校第二附属医院收治的114例新辅助免疫治疗联合化疗后行胃癌根治术的LAGC患者的临床病理资料,按收治时间分为训练集(n=67)和验证集(n=47)。对所有患者治疗前静脉期CT图像进行高通量特征提取,并筛选特征构建影像组学预测模型。采用ROC曲线以及校正曲线评价模型的预测效能,采用Kaplan-Meier曲线评估模型的预后分层能力。
    结果 基于mRMR算法以及LASSO回归模型,本研究在584个特征中筛选出5个特征构建影像组学Rad评分。该评分在训练集和验证集中预测病理完全缓解(pathological complete response,pCR)率的曲线下面积分别为0.865和0.830,且拟合度良好(Hosmer-Lemeshow检验:P>0.05)。根据约登指数确定Rad评分的最佳截点值,高Rad评分的患者其3年无复发生存率(训练集82.7% vs. 60.4%;验证集78.9% vs. 53.8%)、3年总体生存率(训练集78.9% vs. 60.2%;验证集79.3% vs. 50.0%)均显著高于低Rad评分者(P<0.05)。
    结论 CT影像组学预测模型能够有效预测LAGC患者行新辅助免疫治疗联合化疗后的病理学反应及预后,有望成为一个实用的临床工具。

     

    Abstract:
    Objective To investigate the value of a computed tomography (CT) radiomics-based model for predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy for locally advanced gastric cancer (LAGC).
    Methods Data on 114 patients with LAGC who underwent radical surgery after neoadjuvant immunotherapy combined with chemotherapy at The Second Affiliated Hospital of Xingtai Medical College between June 2019 and June 2021 were retrospectively collected. These patients’ data were divided into a training set (n=67) and a validation set (n=47) based on the time of admission. High-throughput features were extracted from baseline portal phase CT images of all patients, and the selected features were used to construct the radiomics prediction model. The predictive performance of the model was evaluated using receiver operating characteristic (ROC) and calibration curves. The prognostic ability of the model was assessed using Kaplan–Meier curves.
    Results Based on the maximum relevancy min-redundancy (mRMR) algorithm and least absolute shrinkage and selection operator (LASSO) regression model, 5 out of 584 assessed features were incorporated into the radiomics (Rad) score. The respective areas under the curve for predicting pathological complete response (pCR) in the training and validation sets were 0.865 and 0.830, respectively, and good fits were obtained (Hosmer-Lemeshow test: P>0.05). The optimal cut-off value for the Rad score was determined based on the Youden index. Patients with high Rad scores had significantly higher 3-year recurrence-free survival rates (82.7% vs. 60.4% in the training set and 78.9% vs. 53.8% in the validation set) and 3-year overall survival rates (78.9% vs. 60.2% in the training set and 79.3% vs. 50.0% in the validation set) than those with low Rad scores (P<0.05).
    Conclusions The CT radiomics prediction model effectively predicted the pathological response and prognosis of patients with LAGC after neoadjuvant immunotherapy combined with chemotherapy and is expected to serve as a practical clinical tool.

     

/

返回文章
返回